Vaxcyte Inc. Common Stock vs Toyota Motor Corp — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Toyota Motor Corp trades at $192.52 (market cap $221.69B). The key difference: Toyota Motor Corp is far larger — about 21.1× Vaxcyte Inc. Common Stock's market cap, and Toyota Motor Corp pays a 3.32% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Toyota Motor Corp for 116 Days on average.
| PCVX | TM | |
|---|---|---|
Market Cap | $10.51B | $221.69B |
Volume | 2,644,694 | 298,766 |
Sector | Health | Consumer Cyclical |
52-Week High | $73.82 | $248.29 |
52-Week Low | $40.32 | $166.50 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $9.14B | $414.72B |
Dividend Yield | — | 3.32% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Toyota Motor trades at $188.60, up 2.1% with bearish technical signals but strong fundamentals. The stock shows attractive valuation with P/E of 8.5 and P/S of 0.74, supported by consistent earnings beats. Recent news highlights growing U.S. market share and electrification progress, though China sales remain a concern. Cash flow trends show recovery from 2025's negative position to projected $2.25T positive in 2026.
Toyota presents a value opportunity with solid profitability and market positioning, though technical weakness and China headwinds warrant caution. The 37.5% buy rating from analysts reflects divided sentiment despite strong fundamentals. Key catalysts include electrification expansion and U.S. market gains, while risks involve production disruptions and competitive pressures in key markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →